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Abstract: High-mobility group box 1 protein (HMGB1), a member of highly conserved 
non-histone DNA binding protein family, has been studied as transcription factor and 
growth factor. Secreted extracellularly by activated monocytes and macrophages or 
passively released by necrotic or damaged cells, extracellular HMGB1 is a potent mediator 
of inflammation. Extracellular HMGB1 has apparently contrasting biological actions: it 
sustains inflammation (with the possible establishment of autoimmunity or of  
self-maintaining tissue damage), but it also activates and recruits stem cells, boosting tissue 
repair. Here, we focus on the role of HMGB1 in physiological and pathological responses, 
the mechanisms by which it contributes to tissue repair and therapeutic strategies base on 
targeting HMGB1. 
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1. Introduction 
This Review article focuses on the biology of high-mobility group box 1 protein (HMGB1; also 
known as amphoterin or HMG1), an evolutionarily ancient protein that was discovered recently to 
have also a role as a cytokine. HMGB1 probably originated more than 500 million years ago, before 
the split between the animal and plant kingdoms. The characteristic double HMG-box organization of 
HMGB1 that is found in metazoans indicates that HMGB1 probably had a cytokine-like role before 
extensive gene duplication occurred in the genome, which then resulted in the emergence of paired 
cytokines and cytokine receptors. 
It was first identified in 1973 as one of a group of chromatin-associated protein with high acidic and 
basic amino acid content [1]. HMGB1 is composed of two tandem DNA binding HMG-box domains 
(N-terminal A and central B), and an acidic C-terminal tail, mediating protein-protein interactions  
(see Figure 1). This structure confers HMGB1 the peculiar feature to recognize and specifically bind 
DNA structures, containing sharp bends or kinks, such as four way junctions [2,3], DNA damaged by 
the anticancer drug cisplatin [4] and by UV-light [5], or to induce bending in linear duplex DNA. The 
structure-specific DNA binding is attributed to the A box [6] while the DNA bending capacity is 
primarily related to the B domain [7]. The abilities of HMGB1 to bend DNA and to bind bent DNA 
define this protein as an architectural factor, promoting the assembly of nucleoprotein complexes. This 
crucial role explains the implication of HMGB1 in mediating fundamental cellular events such as 
transcription, recombination, replication and repair. The nuclear functions of HMGB1 are critical for 
survival as HMGB1í/í mice are born alive but die within 24 h due to hypoglycaemia [8]. Moreover, 
cell lines lacking HMGB1 grow normally, but the activation of gene expression by different signal 
molecules is impaired [8]. 
Figure 1. Scheme of high-mobility group box 1 (HMGB1) structure. 
 
More recently, it has been identified as extracellular signaling molecule able to induce different  
cell responses including cell motility, proliferation, differentiation, and cytokine/chemokine  
production [9,10].  
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HMGB1 can be released actively, by stimulated cells, or passively, by necrotic cells [11]. 
3DUWLFXODUO\³QHFURWLF+0*%´EHKDYHVDVDGDPDJH-associated molecular pattern (DAMP) molecule, 
participating to initiation of reparative responses [12]. In contrast to necrosis, HMGB1 release seems 
to not occur during apoptosis [13], although Pisetsky and collaborators observed HMGB1 leaks out of 
apoptotic cells [14]. During the active release, HMGB1 undergoes different post-translational 
modifications, including hyper-acetylation, phosphorylation and ADP-ribosylation that facilitate 
HMGB1 dissociation from chromatin and, thus, its translocation to the cytoplasm where it is packaged 
into specialized secretory lisosomes [15±17]. 
7KLV ³QRQ-FODVVLFDO´ DFWLYH UHOHDVH PHFKDQLVP LV &D2+-dependent [18]. Moreover, some authors 
suggest that also the redox state of the released forms of HMGB1 is crucial for its extracellular 
activities [19]. 
The different effects exerted by extracellular HMGB1 on specific target cells have been related to 
the ability of this protein to interact with alternative cell surface receptors, such as the receptor for 
advanced glycation end products (RAGE) and the toll-like receptors (TLRs) 2 and 4 [20,21]. 
However, a number of observations indicate that HMGB1 can also act as a co-stimulating accessory 
protein without association with these receptors [11,22]. 
Wound repair is a process requiring local cellular and biochemical events, activated by several 
molecular mediators and interaction of numerous cell types. Growth factors and released cytokines 
during the wound play a crucial role in orchestrating the regenerative process which occurs during 
inflammation, proliferation and remodeling [23]. 
A number of observations indicate that all cell types involved in tissue-repair mechanism are 
sensitive to extracellular HMGB1 and express functional HMGB1 receptors. Indeed, this cytokine-like 
protein acts as chemoattractant and pro-motogenic/pro-mitogenic stimulus for fibroblasts, 
keratinocytes, endothelial cells, vascular smooth muscle cells and vessel-associated stem cells 
(mesangioblast) [24±31]. 
Moreover, HMGB1 can recruit neutrophils, monocytes and macrophages to flamed injured tissues, 
and it is able to induce the production and release of cytokines, chemokines and other important signal 
molecules by innate immune system cells [32]. 
A better understanding of HMGB1 role in tissue repair mechanisms can contribute to a further 
development of regenerative medicine. 
2. High-mobility Group Box 1 (HMGB1) Structure 
Structurally, HMGB1 consists of 215 residues organized in three main functional domains: the A 
and B boxes (positively charged) and the acidic tail (negatively charged). The A and B boxes, residues 
1±79 and 89±163 respectively, are functionally DNA-binding domains [33,34]. 
The C-terminal acidic tail, residues 186±215, plays an important role in nuclear functions [35,36]. 
At the N-terminus of HMGB1 (residues 6±12) is an heparin-binding sequence that likely contributes to 
the heparin and heparin sulphate binding capacity of HMGB1. Recombinant analysis of the protein 
shows that B box contains the cytokine-like activity, inducing macrophage secretion of additional 
proinflammatory cytokines [37]. HMGB1 cytokine activity is antagonized by the recombinant A box, 
whereas in the recombinant B box the residues 89±109 represent the minimal peptide sequence with 
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cytokine activity. Moreover, in the B box is located a short 10 amino acid peptide (residues 130±139), 
produced by proteolytic processing of extracellular HMGB1, active in erythroleukaemia cell 
differentiation [38]. Interestingly, this bioactive peptide is localized between the TLR4 and the RAGE 
bindLQJVLWHV LGHQWLILHG LQWKH%ER[RI+0*%DQGGRHVQ¶WRYHUODSZLWKWKHP7KH5$*(ELQGLQJ
motif is located between residues 150-183, downstream from peptide 130±139, whereas the TLR4 
binding site is a 20-mer peptide stretch containing C106, upstream from peptide 130-139 [19,20]. 
Furthermore, in the primary structure are present three cysteine residues (C23, C45 and C106) 
crucial for the biological activities of extracellular HMGB1. To exert its cytokine-like functions, 
HMGB1 predominant form must contain a C106 thiol group and a disulfide bond between C23 and 
C45, whereas the inactive form of HMGB1 contains terminally oxidized cysteines [19,39]. Oxidation 
of HMGB1 could take place during pathological conditions, such as prolonged ischemia and liver 
transplantation, sterile injury, crush injury, and autoimmune-mediated tissue damage [19,40].  
Interestingly, oxidative stress has been linked to aging, cancer and other diseases in humans [41]. 
Moreover, chemotactic activities of HMGB1 are associated with a different, yet to be characterized, 
SDWWHUQRIF\VWHLQHUHGR[PRGLILFDWLRQV,W¶V OLNHO\WKDW³FKHPRWDFWLF+0*%´FRUUHVSRQGVWRDIXOO\
reduced form, since recombinant HMGB1, supplemented with dithiothreitol (DTT), promotes cell 
migration, although it is unable to induce TNF production [39]. 
3. HMGB1 Receptors 
The pleiotropic functions exerted by extracellular HMGB1 on specific target cells have been related 
to the ability of this protein to engage and activate different receptors, such as RAGE and TLRs 2, 4 
and 9 [42]. RAGE is a member of the Ig superfamily of transmembrane protein and is expressed on 
several cell types, such as endothelial cells, vascular smooth muscle cells, monocytes and 
macrophages, dendritic cells, neurons and glial cells [43].  
RAGE is a 35 kD transmembrane receptor of the immunoglobulin super family which was first 
characterized in 1992 by Neeper et al. [44]. Its name comes from its ability to bind advanced glycation 
end products (AGE), which include chiefly glycoproteins such as the glycans of which have been 
modified non-enzymatically through the Maillard reaction.  
RAGE engagement by HMGB1 leads to the activation of various signal transduction pathways, 
including small GTPases, mitogen activated protein kinases, stress activated protein kinases, and  
NK-kB, and culminates in cell responses ranging from cell motility to cell proliferation, including 
production and release of cytokines/chemokines. The Kd of the HMGB1/RAGE complex is 
approximately 10 nM [10].  
Interestingly, RAGE blockade suppresses the HMGB1 effects, but only partially, strongly 
suggesting the existence of additional receptors for HMGB1. Indeed, the functional association of 
HMGB1 with some members of the TLRs family is widely documented. In this respect, both TLR2 
and 4 are involved in HMGB1-induced pro-inflammatory activation of macrophages and neutrophils. 
Of note, HMGB1 alone is able to activate TLR4 (Yang and co-authors [19] observed an apparent Kd of 
the HMGB1/TLR4 of 1.5 PM), whereas for the activation of TLR2 and 9, HMGB1 has to form 
complexes with apoptotically released nucleosomes and ssDNA, respectively [42]. Since also TLRs 
blockade does not completely abolish HMGB1 effect and HMGB1 can exert some of its biological 
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activities at sub-nanomolar concentrations (so far away from the Kd values for RAGE and TLR4), the 
possibility that other not yet identified HMGB1 receptors exist is actual.  
7KH LGHQWLILFDWLRQ RI ³QHZ´ UHFHSWRUV PLJKW EH D FUXFLDO FKDOOHQJH LQ XQGHUVWDQGLQJ +0*%
biology. Moreover, a synergism between HMGB1 and LPS has been reported for TLR4 activation, as 
well as between HMGB1 and IL-1E in triggering inflammation through IL-1R engagement [22,45]. 
Recently, a new receptor mediating HMGB1 effects has been identified: Pedrazzi and  
colleagues [46] demonstrate that at concentrations of agonist per se ineffective, HMGB1 potentiates 
the activation of the ionotropic glutamate N-methyl-D-aspartate receptor (NMDAR), interacting with 
the ion channel through the sequence corresponding to the peptide located in the B box at the amino 
acids 130±139. 
Thus, the biological activities of extracellular HMGB1 can be modulated at different levels 
including its release, the post-transductional modifications, the redox state, and the possibility to 
engage different receptors on the basis of its extracellular concentration, the presence of co-stimulatory 
molecules, and the Kd values of the signaling complexes. 
4. Tissue Regeneration 
During evolution, multicellular organisms have developed mechanisms to counteract  
life-threatening events such as infections and tissue injury, as well as to restore tissue homeostasis. 
7KHVH PHFKDQLVPV DUH FDOOHG ³WKH LQIODPPDWRU\ UHVSRQVH´ 7R LQLWLDWH DQ DSSURSULDWH LQIODPPDWRU\
response, organisms have developed ways to recognize potentially life-threatening events [47]. 
Trauma and tissue damage trigger an inflammatory response, which is required for post-injury 
regeneration and tissue repair. Inflammation following tissue damage is a dynamic process, which is 
driven by numerous inflammatory mediators [47]. Endogenous danger signals released from necrotic 
or stressed cells that trigger the inflammatory response after trauma have been termed alarmins or 
danger-associated molecular patterns (DAMPs) [48]. DAMPs share structural and functional 
similarities with exogenous, conserved microbial surface structures released from invading 
microorganisms, so-called pathogen-associated molecular patterns (PAMPs). However, this definition 
of DAMPs is not always used consistently, and sometimes endogenous alarmins and exogenous 
PAMPs are collectively classified as danger-associated molecular patterns (DAMPs).  
Well-known alarmins include but are not limited to heat shock proteins, hyaluronan, uric acid, 
galectins, thioredoxin, adenosine, HMGB1, interleukin-Į,/-ĮDQGLQWHUOHXNLQ-33 (IL-33) [49]. As 
unique features, HMGB1, IL-ĮDQG ,/-33 exert dual functions as intracellular transcription factors 
and as extracellular inflammatory mediators [50]. 
Several instances of HMGB1 as released by damaged tissues are well described. The damage can 
be caused not only by trauma, but also by the immune system itself [51]. 
Acute liver injury, such as that following ischemia and reperfusion of the organ, causes the rapid 
release of HMGB1, which triggers inflammation. Likewise, after the killing of hepatocytes by hepatitis 
virus B-specific cytotoxic T lymphocytes, HMGB1 directs the recruitment of neutrophils and of all 
others non-antigen specific inflammatory cells [52]. 
The role of HMGB1 as chemo attractant for inflammatory cells is thus out of the debate and the 
receptor involved in this phenomenon is the receptor for advanced glycation end product (RAGE).  
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RAGE knock-out mice are viable and are less susceptible to sepsis. Some findings, such as the 
chemotactic responses in RAGEí/í derived fibroblasts to HMGB1 [53], raised the possibilities that 
chemotactic and tissue repair activities of HMGB1 are not mediated only by RAGE. 
It is also to note that among RAGE ligands, HMGB1 appears to play an important role in cancer. 
Many reports point out the significance of ligand/RAGE interactions in carcinogenesis, tumor 
progression and metastasis [54]. Some studies on the HMGB1/RAGE interactions revealed that this 
complex played a pivotal role in neurite outgrowth through activation of two small GTPases of the 
Rho family, Cdc42 and Rac1, thus suggesting that HMGB1/RAGE signaling might be associated with 
cancer metastasis [55]. HMGB1 was found to bind RAGE in a variety of cells such as neurons, 
endothelium, smooth muscle, monocytes, macrophages, T-cells and immature dendritic cells. 
Moreover, ligation of HMGB1 to RAGE triggered events such as endothelial cell activation [32].  
HMGB1 fulfills the prediction that a signal from damaged tissue should promote their regeneration. 
In in vitro in absence of serum, HMGB1 acts as mitogen for several cell types, such as 
mesoangioblasts and endothelial precursor cells [26,56,57]. 
HMGB1 behaves as a trigger of tissue repair, recruiting stem cells, and promoting their 
proliferation [58]. Some studies on regenerative properties of HMGB1 have been performed on 
experimental models in skeletal and cardiac muscles. HMGB1 levels are increased in reparation of 
skeletal muscle and the intramuscular injection of HMGB1 increases the number of regenerating  
fibers [59]. Moreover, HMGB1 induces an increase of stem cells transmigration across the endothelial 
barrier. In addition, HMGB1 is able to induce myogenic differentiation via Cdc42-Rac1-MAPKs. 
HMGB1 stimulates also the migration of rat smooth cells, inducing rapid and transient changes in cell 
shape and actin reorganizations [60]. 
HMGB1 also promotes heart regeneration after infarction. Injection of HMGB1 into mouse hearts 
after ischaemic damage resulted in the formation of new myocytes. Indeed, HMGB1 induced c-kit+ 
cardiac stem-cell proliferation and differentiation. Interestingly, differentiation towards the myocardial 
lineage was not observed in non-infarcted HMGB1-treated hearts, suggesting that signals released 
from damaged tissue are required for differentiation [61]. 
HMGB1 is also necessary for the transfilter migration of glioma cells and that migration is inhibited 
by antibodies against the RAGE-binding domain of HMGB1. By studying nerve crush injuries, 
Rauvala and coworkers determined that HMGB1 messenger RNA is present in cell bodies before 
injury but is only translated into protein after injury. Thus, it is possible to postulate that HMGB1 is a 
danger signal that is locally translated in injured axons to enhance regeneration of the nerve  
processes [62]. 
With regards to angiogenesis, HMGB1 is able to induce the formation of new blood vessels through 
various pathways, including upregulation of pro-angiogenetic factors, promoting the homing of 
endothelial progenitor cells and sprouting [63]. 
Given its potent extracellular functions, it is likely that HMGB1 is counteracted by inhibiting 
molecules. Endothelial thrombomodulin binds HMGB1 through its lectin-binding domain and thereby 
dampens inflammation. Thrombomodulin inhibited HMGB1-induced NF-ț%WUDQVORFDWLRQ in vitro and 
decreased ultraviolet-induced skin inflammation in vivo [64]. 
Cytokine-induced cell proliferation and migration are also fundamental elements of skin repair. 
Growth factors are thought to be main intercellular signaling that orchestrates the complex sequence of 
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wound healing-related cell activities [47]. Due to the observed pro-inflammatory role of HMGB1, and 
its ability to induce cell proliferation and motility, HMGB1 has been proven to possess this kind of 
property on keratinocytes and fibroblasts [24,25]. 
The physiological meaning of this property in cutaneous wound healing remains to be ascertained. 
Straino and coworkers [50] have shown that HMGB1 levels are reduced in the skin of both diabetic 
human and mice, having impaired tissue repair and report different mechanisms by which HMGB1 
may promote wound healing. These findings fit a recent view assuming that many elements, such as 
HMGB1, could EH FRPELQHG WR UHFUHDWH D UHFHSWLYH HQYLURQPHQW RU ³VRLO´ZKLFK LQ FRPELQDWLRQ
ZLWK WKH DSSURSULDWH VWHP FHOOV RU ³VHHG´ ZRXOG SURYLGH D IRUFH IRU WLVVXH UHSDLU DQG 
regeneration [65]. 
So, it is possible to postulate that HMGB1 release may occur in vivo from skin cells, such as 
fibroblasts and keratinocytes, as the result of cell activation, enhanced membrane permeability, or 
membrane ruptures. After its release in the wounded area, HMGB1 could operate the recruitment of 
different cell types, and influence keratinocyte and fibroblast proliferation and migration [24,25]. 
HMGB1 could trigger and strengthen the healing cascade and this could be relevant to long-term 
effects on wound healing and tissue repair. These kind of processes are of great interest for the 
treatment of tissue lesions occurring in certain diseases, e.g., diabetes, in which cells are shown to be 
less responsive to growth factors [66]. 
Of particular interest is the HMGB1 sensitivity to oxidation [67]. Oxidative stress is an early player 
in acute inflammatory response; it elicits the formation of reversible covalent disulfide bonds between 
thiols [68]. HMGB1 contains three cysteine residues at positions 23, 45 and 106. Mild oxidation status 
induces the formation of an intramolecular disulfide bond between cysteines in position 23 and 45. 
These residues are also implicated in the binding of HMGB1 to Toll-like receptor 4 [69].  
An oxidized environment could modulate HMGB1 functions. Some authors have suggested that 
oxidation could quench HMGB1 inflammatory effects. In this scenario, a reduced environment could 
sustain and prolong HMGB1 bioactivity, but further studies are needed to verify these hypotheses. 
5. Conclusions 
The dual-function of HMGB1 represents a crucial mediator in the initiation and perpetuation of the 
inflammatory response following loss of cellular integrity.  
Basic research as well as clinical studies is strongly needed to further unravel the complexity of the 
host response after trauma and tissue damage.  
Novel preclinical models of trauma may help characterize the role of DAMPs and investigate 
mechanisms/kinetics of release after tissue injury in single-organ injury and multi-system trauma.  
In addition, little is known about mutual interactions of DAMPs prior and after passive or active 
release and direct crosstalk with other mediators of inflammation and signaling systems.  
As regards potential therapeutic strategies, alongside agents that neutralize or block DAMPs, the 
development of compounds that cause intracellular DAMP retention and limit DAMP release upon 
tissue damage might represent a promising approach.  
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